# Declarations of Interest

## Professor Rustam Al-Shahi Salman

No major competing interests other than what is declared here (http://www.whopaysthisdoctor.org/doctor/276).

### **Professor Jesse Dawson**

None relevant to hypertension but more widely honoraria from Bayer, BMS, Pfizer, Boeringher Ingelheim.

## Mr Paul Forsyth

No declarations related to hypertension or the medications used to treat it but more widely honoraria from Novartis, Vifor, Astrazeneca and Servier.

## **Professor Anne Hendry**

I carry out some occasional expenses only consultancy for WHO and the International Foundation for Integrated Care (both NGOs) and am on the board of the Alliance Academy.

#### Professor Isla Mackenzie

| Professor Isla Mackenzie   |   |
|--|---|
| DECLARATION OF INTERESTS   | PROFESSOR ISLA MACKENZIE 28/09/2018   |
| Employment   | – University of Dundee αnd NHS Tayside  |
| Other Appointments (voluntary or otherwise) e.g. trusteeships, directorships, positions of office    | <ul> <li>Trustee of Scottish Heart and Arterial disease Risk Prevention (SHARP) Group</li> <li>Representative of the Faculty of Pharmaceutical Medicine on College Council, Royal College of Physicians, Edinburgh</li> <li>RCPE Representative on Faculty of Pharmaceutical Medicine Board</li> <li>Chief Medical Officer's Specialty Adviser in Clinical Pharmacology</li> <li>Member of British &amp; Irish Hypertension Society Research Working Party</li> <li>Honorary Secretary and Trustee of Scottish Society of Physicians</li> <li>Membership and Awards Committee of British Pharmacological Society</li> <li>Clinical Committee of British Pharmacological Society</li> <li>Specialist Member National Antidoping Panel</li> </ul> |
| Membership of any professional bodies, special interest groups or mutual support organisations       | <ul> <li>British &amp; Irish Hypertension Society (Fellow)</li> <li>British Pharmacological Society (Fellow)</li> <li>Caledonian Society of Clinical Pharmacology</li> <li>Digital Health Institute</li> <li>International Society for Pharmacoepidemiology</li> <li>Royal College of Physicians Edinburgh (Fellow)</li> <li>Scottish Heart and Arterial disease Risk Prevention (SHARP) Group</li> <li>Scottish Society of Physicians</li> </ul>   |
| Membership of any professional<br>bodies, special interest groups or<br>mutual support organisations | In the last 5 years I have received academic research grants from BHF, Menarini, Novartis, Anonymous Trust, Multiple Sclerosis National Therapy Centres, NIHR HTA, Amgen Ltd, Clinical Endocrine Trust (via Queen Mary University of London), RTI, Tenovus Scotland, George Clinical and European Medicines Agency. I have received an honorarium from MSD and AstraZeneca.   |

# Professor Brian McKinstry

I am clinical lead for the Scottish Government TEC fund rollout of Scale Up BP and have been funded by several government and EU funders to carry out research in the remote management of high blood pressure.

# Professor Sandosh Padmanabhan

My research is focussed on hypertension genetics, epidemiology and clinical trials which are funded by the British Heart Foundation and Medical Research Council. I am a Glasgow Principal Investigator of the CALM-2 trial for Vascular Dynamics. I am also a founder and director of Kvatchii Ltd, a University of Glasgow digital health spinout company.

# Professor Rhian Touyz

My research is supported by the British Heart Foundation, Medical Research Council, and the Chief Scientific Office. I have also consulted for Novartis and Alnylam. I am the Deputy Editor of the journal Hypertension. I have no other relevant conflicting interests.

# Professor David Webb

I am UK Chief Investigator for the PRECISION study, funded by a pharmaceutical company, Idorsia, which looks at a new medicine (aprocitentan) for treatment-resistant hypertension. My department receives a grant for this study, but I receive no funds for the work, so this is a non-personal hypertension-specific interest. My research is otherwise funded by the British Heart Foundation and Kidney Research UK. I am Vice Chair of the Unitary Board of the Medicines and Healthcare products regulatory Agency (MHRA), and have roles within the British Pharmacological Society (BPS) and International Union of Basic and Clinical Pharmacology (IUPHAR), but these should not generate conflicts in relation to this project.